Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD22 CAR-expressing T cells SCRI-CAR22v2

A preparation of autologous human T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD22 CAR-expressing T cells SCRI-CAR22v2 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces leading to lysis of CD22-expressing B cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD22 CAR T cells SCRI-CAR22v2
autologous CD22-CAR-expressing T lymphocytes SCRI-CAR22v2
Code name:SCRI CAR22v2
SCRI-CAR22v2
SCRICAR22v2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search